In contrast, in non-small cell lung cancer (NSCLC), Rb mutation accounts for 15–30% of these cancers [26], [28], and deregulation of the CDK/Rb/E2F pathway more commonly occurs via silencing of the CDK inhibitor p16 [29]–[32]. The gene discussed is CDKN2A; the disease is non-small cell lung carcinoma.